Anti-Rheumatic Drugs - North America

  • North America
  • The Anti-Rheumatic Drugs market in North America is expected to witness impressive growth in the coming years.
  • According to projections, the revenue in this market is set to reach US$35.39bn by 2024.
  • Furthermore, it is anticipated to exhibit a steady annual growth rate (CAGR 2024-2029) of -1.23%, leading to a market volume of US$33.27bn by 2029.
  • When compared globally, it is noteworthy that United States will generate the highest revenue in this market, with an estimated value of US$34,700.00m in 2024.
  • The North American region, particularly United States, holds significant potential in the Anti-Rheumatic Drugs market.
  • In North America, the demand for innovative anti-rheumatic drugs is on the rise, driven by a growing aging population and increased awareness about the benefits of early treatment.

Key regions: Germany, United States, India, Japan, United Kingdom

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The demand for Anti-Rheumatic Drugs in North America has been on the rise in recent years.

Customer preferences:
Patients suffering from rheumatoid arthritis and other related diseases in North America prefer Anti-Rheumatic Drugs due to their effectiveness in reducing inflammation and providing relief from pain. The increasing aging population and sedentary lifestyle have also contributed to the growing demand for these drugs.

Trends in the market:
The Anti-Rheumatic Drugs market in North America has witnessed a shift towards biologic drugs due to their higher efficacy and lower side effects compared to traditional disease-modifying anti-rheumatic drugs (DMARDs). Additionally, there has been an increase in the use of combination therapies, where biologic drugs are used in combination with DMARDs, to achieve better outcomes.

Local special circumstances:
The United States has the largest market share in North America due to the high prevalence of rheumatoid arthritis and other related diseases. The market in Canada is also growing due to the increasing awareness and availability of advanced treatments. However, the market in Mexico is relatively small due to the lack of access to advanced healthcare facilities and low awareness about rheumatic diseases.

Underlying macroeconomic factors:
The North American market for Anti-Rheumatic Drugs is driven by factors such as increasing healthcare expenditure, favorable government initiatives, and technological advancements in drug development. The growing prevalence of rheumatoid arthritis and related diseases, especially among the aging population, is also contributing to the market growth. However, the high cost of biologic drugs and the availability of alternative therapies are some of the factors that may hinder market growth in the future.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Key Players
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)